Nanobody Conjugates for Targeted Cancer Therapy and Imaging

Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, lo...

Full description

Saved in:
Bibliographic Details
Published inTechnology in cancer research & treatment Vol. 20; p. 15330338211010117
Main Authors Kang, Wei, Ding, Chuanfeng, Zheng, Danni, Ma, Xiao, Yi, Lun, Tong, Xinyi, Wu, Chuang, Xue, Chuang, Yu, Yongsheng, Zhou, Qian
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.01.2021
Sage Publications Ltd
SAGE Publishing
Subjects
Amino acids
Antibodies
Antigens
Binding sites
Bioengineering
Cancer
Cancer research
Cancer therapies
Chemical bonds
Crystal structure
Cytotoxicity
Epidermal growth factor
Fluorophores
Immunogenicity
Medical research
Nanobodies
Pharmacokinetics
Proteins
Review
Side effects
Targeted cancer therapy
Tomography
Toxins
Tumor cells
antibody fragments
therapeutic nanobodies
targeted caner treatment
nanobodies
bioconjugations
cancer imaging
Online AccessGet full text

Cover

Abstract Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.
AbstractList Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.
Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.
Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.
Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.
Author Ding, Chuanfeng
Wu, Chuang
Yi, Lun
Kang, Wei
Zhou, Qian
Yu, Yongsheng
Zheng, Danni
Xue, Chuang
Ma, Xiao
Tong, Xinyi
AuthorAffiliation 1 School of Bioengineering, Dalian University of Technology, Dalian, China
2 Ningbo Institute of Dalian University of Technology, Ningbo, China
4 Xiamen Medical College, Xiamen, China
3 Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
AuthorAffiliation_xml – name: 3 Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
– name: 1 School of Bioengineering, Dalian University of Technology, Dalian, China
– name: 4 Xiamen Medical College, Xiamen, China
– name: 2 Ningbo Institute of Dalian University of Technology, Ningbo, China
Author_xml – sequence: 1
  givenname: Wei
  orcidid: 0000-0002-2288-3540
  surname: Kang
  fullname: Kang, Wei
– sequence: 2
  givenname: Chuanfeng
  surname: Ding
  fullname: Ding, Chuanfeng
– sequence: 3
  givenname: Danni
  surname: Zheng
  fullname: Zheng, Danni
– sequence: 4
  givenname: Xiao
  surname: Ma
  fullname: Ma, Xiao
– sequence: 5
  givenname: Lun
  surname: Yi
  fullname: Yi, Lun
– sequence: 6
  givenname: Xinyi
  surname: Tong
  fullname: Tong, Xinyi
  email: yongshengyu@tongji.edu.cn
– sequence: 7
  givenname: Chuang
  surname: Wu
  fullname: Wu, Chuang
– sequence: 8
  givenname: Chuang
  surname: Xue
  fullname: Xue, Chuang
  email: xue.1@dlut.edu.cn
– sequence: 9
  givenname: Yongsheng
  orcidid: 0000-0001-5139-3439
  surname: Yu
  fullname: Yu, Yongsheng
  email: yongshengyu@tongji.edu.cn
– sequence: 10
  givenname: Qian
  surname: Zhou
  fullname: Zhou, Qian
  email: shzhouqian@126.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33929911$$D View this record in MEDLINE/PubMed
BookMark eNp9UtFuFCEUJabGtqsf4IuZxBdftnKBGSAmJmZj6yaNvtRncgeY6WxmYYXZJvv3st222hobHoDDOSfncu8pOQoxeELeAj0DkPIj1JxTzhUDoGWBfEFO9th8Dx49nEVzTE5zXlHKmobDK3LMuWZaA5yQT98xxDa6XbWIYbXtcfK56mKqrjD1fvKuWmCwvtyvfcLNrsLgquUa-yH0r8nLDsfs39ztM_Lz_OvV4tv88sfFcvHlcm7rhk5zJRuHtlXCMt9RbpmzTlOqpFW8rRUggnQe0LeUt7T1NaLTBbba1YIJzWdkefB1EVdmk4Y1pp2JOJhbIKbeYJoGO3rTCI5SA9egGqE7i0pRkG1tWUdr2bXF6_PBa7Nt195ZH6aE4yPTxy9huDZ9vDEKAGrRFIMPdwYp_tr6PJn1kK0fRww-brNhNSulgbylvn9CXcVtCuWrDGecCdEoxp9jsQY400qUJs_Iu79zPwS-72QhyAPBpphz8p2xw4TTEPdlDKMBavYzY_6ZmaKEJ8p78-c0ZwdNxt7_Cfx_wW-CD8xV
CitedBy_id crossref_primary_10_1186_s12951_024_02900_y
crossref_primary_10_3390_cancers15133493
crossref_primary_10_1002_adtp_202300076
crossref_primary_10_3390_pharmaceutics15102374
crossref_primary_10_1007_s11030_024_11086_2
crossref_primary_10_3390_ijms241713229
crossref_primary_10_1186_s12935_024_03259_8
crossref_primary_10_3390_ijms232213687
crossref_primary_10_3390_cancers16152681
crossref_primary_10_3892_ijmm_2023_5336
crossref_primary_10_1007_s43152_023_00044_z
crossref_primary_10_1016_j_addr_2023_114726
crossref_primary_10_1021_acsnano_2c12733
crossref_primary_10_1021_acs_bioconjchem_3c00374
crossref_primary_10_21931_RB_2023_08_02_13
crossref_primary_10_1007_s00259_025_07087_4
crossref_primary_10_1093_abt_tbae005
crossref_primary_10_3390_antib11040078
crossref_primary_10_1016_j_bbcan_2025_189284
crossref_primary_10_1016_j_intimp_2023_110999
crossref_primary_10_1016_j_lfs_2024_122593
crossref_primary_10_1016_j_canlet_2023_216191
crossref_primary_10_1016_j_jconrel_2023_05_031
Cites_doi 10.1016/j.nano.2013.12.007
10.1093/oxfordjournals.molbev.a003988
10.1093/protein/gzv032
10.1158/0008-5472.CAN-05-0542
10.1021/acs.molpharmaceut.9b00360
10.1038/s41467-018-07131-y
10.1016/j.bbagen.2013.04.023
10.1038/nrc.2017.11
10.1016/j.jconrel.2013.08.298
10.3390/cancers12030738
10.1007/s00280-015-2712-0
10.1158/0008-5472.CAN-03-3935
10.1016/j.vetimm.2008.10.299
10.1002/anie.201507596
10.1186/s13550-016-0166-y
10.1073/pnas.0505379103
10.1002/cbic.201500009
10.1586/era.13.16
10.1517/13543784.2012.656197
10.1007/s00259-013-2471-2
10.1126/science.aaa5026
10.1093/protein/7.9.1129
10.1016/j.jmb.2007.08.027
10.2967/jnumed.108.060392
10.2310/7290.2011.00025
10.1158/1535-7163.MCT-18-0849
10.1089/104303403767740786
10.1038/celldisc.2017.4
10.2967/jnumed.118.224170
10.1083/jcb.201409074
10.1007/s11307-008-0133-8
10.1126/scitranslmed.aac5415
10.3390/cancers11060872
10.1016/j.jconrel.2016.03.014
10.1186/s12951-018-0392-8
10.3390/antib8040055
10.2967/jnumed.112.111021
10.1038/clpt.2010.12
10.7150/thno.8156
10.1038/363446a0
10.1146/annurev-biochem-063011-092449
10.1056/NEJMoa1817226
10.1038/s41556-018-0236-7
10.7554/eLife.11349
10.1007/s00253-005-0300-7
10.1038/nsb0996-803
10.1073/pnas.1202832109
10.2967/jnumed.120.255679
10.1038/nrc1893
10.1021/acs.bioconjchem.5b00602
10.1002/jgm.2604
10.1038/s41591-018-0255-8
10.1126/science.1060077
10.1021/bc500111t
10.1128/AEM.71.1.442-450.2005
10.4161/mabs.2.1.10786
10.1038/nmeth953
10.1016/j.nucmedbio.2016.01.002
10.1002/psc.2996
10.4049/jimmunol.175.6.3769
10.1038/nchembio.720
10.3390/ijms19020403
10.1002/ijc.26145
10.1038/nmeth886
10.1016/j.jconrel.2020.04.030
10.1073/pnas.1912487116
10.3389/fimmu.2017.01442
10.1016/j.vaccine.2005.05.017
10.1002/cmmi.491
10.1186/s12934-019-1053-9
10.1158/2326-6066.CIR-15-0231
10.2967/jnumed.107.048538
10.1007/s12265-012-9435-y
10.1016/j.drudis.2016.04.003
10.4161/19420862.2014.975099
10.1089/cbr.2020.3941
10.1016/j.coph.2003.05.002
10.1371/journal.ppat.1002072
10.1039/C7SC00574A
10.1073/pnas.98.2.777-e
10.3892/ijo.2015.3210
10.1016/j.jmb.2018.09.002
10.1016/j.nbt.2012.09.002
10.1186/s12951-015-0091-7
10.1186/s12929-019-0592-z
10.1002/cbic.201500591
10.1007/s40259-019-00392-z
10.1080/17425247.2016.1178235
10.1038/374168a0
10.2967/jnumed.115.162024
10.1016/j.molmed.2011.12.003
10.1002/ijc.10212
10.1186/s12967-014-0352-5
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021 2021 SAGE Publications
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021 2021 SAGE Publications
DBID AFRWT
AAYXX
CITATION
NPM
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1177/15330338211010117
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic

Oncogenes and Growth Factors Abstracts
PubMed
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1533-0338
ExternalDocumentID oai_doaj_org_article_643a7913918649fca88017b5c2f057fb
PMC8111546
33929911
10_1177_15330338211010117
10.1177_15330338211010117
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 21807043
  funderid: https://doi.org/10.13039/501100001809
– fundername: ;
  grantid: 21807043
GroupedDBID ---
0R~
123
53G
54M
7X7
8FI
8FJ
AAJPV
AAJQC
AARDL
AASGM
ABAWP
ABQXT
ABUWG
ABVFX
ACARO
ACDXX
ACGFS
ACHEB
ACROE
ADBBV
ADOGD
ADPDF
AENEX
AERKM
AEUHG
AEWDL
AFCOW
AFKRA
AFKRG
AFRWT
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AUTPY
AYAKG
BDDNI
BENPR
BPHCQ
BSEHC
BVXVI
CCPQU
DC.
EBS
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HMCUK
HYE
J8X
K.F
O9-
OK1
OVD
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
SAUOL
SCDPB
SCNPE
SFC
SJN
TEORI
UKHRP
Y4B
AAYXX
CITATION
-TM
AABMB
AADCB
AADUE
AARIX
ABEIX
ABFWQ
ABKRH
ABRHV
ACDSZ
ACOFE
ADZZY
AEQLS
AEXNY
AFEET
AFUIA
AGNHF
ALJHS
B8M
BKSCU
CDWPY
CFDXU
DC-
DOPDO
EJD
M4V
NPM
OVEED
UDS
ZONMY
ZPPRI
ZRKOI
ZSSAH
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c560t-876dacb84c2ef03c2dcd90087c83b581aa17de1aeb03b0be5aad981ac9d542493
IEDL.DBID DOA
ISSN 1533-0346
1533-0338
IngestDate Wed Aug 27 01:30:13 EDT 2025
Thu Aug 21 18:40:34 EDT 2025
Fri Jul 11 06:14:14 EDT 2025
Tue Aug 05 06:10:37 EDT 2025
Mon Jun 30 07:56:03 EDT 2025
Thu Apr 03 06:53:25 EDT 2025
Thu Apr 24 22:55:23 EDT 2025
Tue Jul 01 03:10:25 EDT 2025
Sun Jul 27 05:40:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords antibody fragments
therapeutic nanobodies
targeted caner treatment
nanobodies
bioconjugations
cancer imaging
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-876dacb84c2ef03c2dcd90087c83b581aa17de1aeb03b0be5aad981ac9d542493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5139-3439
0000-0002-2288-3540
OpenAccessLink https://doaj.org/article/643a7913918649fca88017b5c2f057fb
PMID 33929911
PQID 2613298430
PQPubID 4450582
ParticipantIDs doaj_primary_oai_doaj_org_article_643a7913918649fca88017b5c2f057fb
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8111546
proquest_miscellaneous_2520871746
proquest_journals_3232446823
proquest_journals_2613298430
pubmed_primary_33929911
crossref_citationtrail_10_1177_15330338211010117
crossref_primary_10_1177_15330338211010117
sage_journals_10_1177_15330338211010117
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
– name: Thousand Oaks
– name: Sage CA: Los Angeles, CA
PublicationTitle Technology in cancer research & treatment
PublicationTitleAlternate Technol Cancer Res Treat
PublicationYear 2021
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Dijkers, Oude Munnink, Kosterink 2010; 87
Keyaerts, Xavier, Heemskerk 2016; 57
Yamaguchi, Matsuda, Ohtake 2016; 27
Oliveira, Heukers, Sornkom, Kok, Henegouwen 2013; 172
Kijanka, Warnders, El Khattabi 2013; 40
Chiu, Goulet, Teplyakov, Gilliland 2019; 8
Xie, Dougan, Jailkhani 2019; 116
Bachmann, Mootz 2017; 23
Gainkam, Huang, Caveliers 2008; 49
D’Huyvetter, Vincke, Xavier 2014; 4
Greenberg, Avila, Hughes, Hughes, Mckinney, Flajnik 1995; 374
Brekke, Loset 2003; 3
Jovcevska, Muyldermans 2020; 34
Muyldermans 2013; 82
Stephanopoulos, Francis 2011; 7
Burg, Ingram, Venkatakrishnan 2015; 347
Gattenlohner, Marx, Markfort 2006; 66
Minchinton, Tannock 2006; 6
Oliveira, van Dongen, van Walsum 2012; 11
Desmyter, Transue, Ghahroudi 1996; 3
Dolk, van der Vaart, Lutje Hulsik 2005; 71
Zhang, Wei, Wang 2017; 3
Nadler, Stashenko, Hardy 1980; 40
Pleiner, Bates, Trakhanov 2015; 4
Bathula, Bommadevara, Hayes 2020; 36
De Genst, Silence, Decanniere 2006; 103
Harmsen, van Solt, van Bemmel, Niewold, van Zijderveld 2006; 72
Russo, Bondanza, Ciceri 2012; 18
Huang, Gainkam, Caveliers 2008; 10
Tsumura, Sato, Furuya 2015; 47
Kijanka, van Brussel, van der Wall 2016; 6
Zou, Smith, Nguyen 2005; 175
Bensch, van der Veen, Lub-de Hooge 2018; 24
Brooks, Fresco, Lesk, Singh 2002; 19
Yan, Wang, Zhu 2015; 13
Raje, Berdeja, Lin 2019; 380
Broos, Lecocq, Xavier 2019; 11
Rothbauer, Zolghadr, Tillib 2006; 3
De Munter, Ingels, Goetgeluk 2018; 19
Patra, Das, Fraceto 2018; 16
Bartunek, Barbato, Heyndrickx, Vanderheyden, Wijns, Holz 2013; 6
Nelson 2010; 2
De Groof, Mashayekhi, Fan 2019; 16
Schumacher, Lemke, Helma 2017; 8
D’Huyvetter, De Vos, Caveliers 2020
Steeland, Vandenbroucke, Libert 2016; 21
Tang, Shah, Messerli, Snyder, Breakefield, Weissleder 2003; 14
Hamerscasterman, Atarhouch, Muyldermans 1993; 363
Xavier, Blykers, Vaneycken 2016; 43
Massa, Xavier, De Vos 2014; 25
Dijkers, Kosterink, Rademaker 2009; 50
Papandrianos, Savvopoulos, Barla 2008; 35
Grillo-Lopez 2013; 13
Niemeijer, Leung, Huisman 2018; 9
Massa, Xavier, Muyldermans, Devoogdt 2016; 13
Xavier, Vaneycken, D’Huyvetter 2013; 54
Wang, Brock, Herberich, Schultz 2001; 292
Muyldermans, Baral, Retarnozzo 2009; 128
Muralidharan, Muir 2006; 3
Zavrtanik, Luken, Loris, Lah, Hadzi 2018; 430
Gray, Tao, DePorter, Spiegel, McNaughton 2016; 17
Porter, Hwang, Frey 2015; 7
van de Water, Bagci-Onder 2012; 109
Tintelnot, Baum, Schultheiss 2019; 18
Harmsen, Van Solt, Fijten, Van Setten 2005; 23
Zah, Lin, Silva-Benedict, Jensen, Chen 2016; 4
Koide, Tereshko, Uysal, Margalef, Kossiakoff, Koide 2007; 373
Xing, Chand, Liu, Cook, O’Doherty, Zhao, Wong, Meszaros, Ting, Zhao 2019; 60
Lu, Hwang, Liu 2020; 27
Huet, Growney, Johnson 2014; 6
Ta, Redeker, Billen 2015; 28
Vaddepally, Kharel, Pandey, Garje, Chandra 2020; 12
Deken, Kijanka, Hernandez 2020; 323
Alderton 2017; 17
van Driel, Boonstra, Slooter 2016; 229
D’Huyvetter, Aerts, Xavier 2012; 7
Dennler, Bailey, Spycher, Schibli, Fischer 2015; 16
Curran, Pegram, Brentjens 2012; 14
Muyldermans, Atarhouch, Saldanha, Barbosa, Hamers 1994; 7
Zhu, Gong, Hu, Ou, Wan 2014; 12
Sleep, Cameron, Evans 2013; 1830
Hu, Liu, Muyldermans 2017; 8
Sarker, Rathore, Gupta 2019; 18
Heukers, Henegouwen, Oliveira 2014; 10
Cortez-Retamozo, Lauwereys, Gh 2002; 98
Lawson, Kessenbrock, Davis, Pervolarakis, Werb 2018; 20
Aboody, Brown, Rainov 2001; 98
Helma, Cardoso, Muyldermans, Leonhardt 2015; 209
Stijlemans, Caljon, Natesan 2011; 7
Behdani, Zeinali, Karimipour 2013; 30
Hernandez, Bott, Patel 2018; 24
Kelly, Lee, Tahtis 2008; 23
Rashidian, Wang, Edens 2016; 55
Peled, Wald, Burger 2012; 21
Papadopoulos, Isaacs, Bilic 2015; 75
Cortez-Retamozo, Backmann, Senter 2004; 64
Roovers, Vosjan, Laeremans 2011; 129
bibr49-15330338211010117
bibr91-15330338211010117
bibr36-15330338211010117
bibr37-15330338211010117
bibr77-15330338211010117
bibr64-15330338211010117
bibr51-15330338211010117
bibr24-15330338211010117
bibr11-15330338211010117
bibr78-15330338211010117
bibr88-15330338211010117
bibr48-15330338211010117
bibr12-15330338211010117
bibr22-15330338211010117
bibr52-15330338211010117
bibr62-15330338211010117
bibr92-15330338211010117
Kelly MP (bibr10-15330338211010117) 2008; 23
bibr38-15330338211010117
bibr2-15330338211010117
bibr63-15330338211010117
bibr53-15330338211010117
bibr9-15330338211010117
bibr19-15330338211010117
bibr93-15330338211010117
bibr79-15330338211010117
bibr89-15330338211010117
bibr13-15330338211010117
bibr33-15330338211010117
bibr87-15330338211010117
bibr8-15330338211010117
bibr20-15330338211010117
Xie YJ (bibr71-15330338211010117) 2019; 116
bibr47-15330338211010117
bibr67-15330338211010117
bibr27-15330338211010117
bibr4-15330338211010117
bibr90-15330338211010117
bibr35-15330338211010117
bibr85-15330338211010117
bibr25-15330338211010117
bibr95-15330338211010117
bibr45-15330338211010117
bibr75-15330338211010117
bibr65-15330338211010117
bibr55-15330338211010117
bibr50-15330338211010117
bibr15-15330338211010117
Aboody KS (bibr61-15330338211010117) 2001; 98
bibr40-15330338211010117
bibr6-15330338211010117
bibr70-15330338211010117
bibr60-15330338211010117
bibr80-15330338211010117
bibr29-15330338211010117
bibr97-15330338211010117
bibr84-15330338211010117
bibr16-15330338211010117
bibr30-15330338211010117
bibr44-15330338211010117
Papandrianos N (bibr23-15330338211010117) 2008; 35
bibr57-15330338211010117
Nadler LM (bibr1-15330338211010117) 1980; 40
bibr17-15330338211010117
bibr31-15330338211010117
bibr42-15330338211010117
bibr68-15330338211010117
bibr32-15330338211010117
bibr72-15330338211010117
bibr58-15330338211010117
bibr28-15330338211010117
bibr82-15330338211010117
bibr18-15330338211010117
bibr73-15330338211010117
bibr43-15330338211010117
bibr69-15330338211010117
bibr83-15330338211010117
bibr59-15330338211010117
bibr26-15330338211010117
bibr81-15330338211010117
bibr39-15330338211010117
bibr46-15330338211010117
bibr74-15330338211010117
bibr94-15330338211010117
bibr3-15330338211010117
Hernandez I (bibr7-15330338211010117) 2018; 24
bibr34-15330338211010117
bibr54-15330338211010117
bibr14-15330338211010117
bibr41-15330338211010117
bibr21-15330338211010117
bibr86-15330338211010117
bibr76-15330338211010117
bibr5-15330338211010117
bibr56-15330338211010117
bibr66-15330338211010117
bibr96-15330338211010117
References_xml – volume: 347
  start-page: 1113
  issue: 6226
  year: 2015
  end-page: 1117
  article-title: Structural biology. structural basis for chemokine recognition and activation of a viral G protein-coupled receptor
  publication-title: Science
– volume: 229
  start-page: 93
  year: 2016
  end-page: 105
  article-title: EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer
  publication-title: J Control Release
– volume: 16
  start-page: 71
  issue: 1
  year: 2018
  article-title: Nano based drug delivery systems: recent developments and future prospects
  publication-title: J Nanobiotechnol
– volume: 6
  start-page: 1560
  issue: 6
  year: 2014
  end-page: 1570
  article-title: Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
  publication-title: Mabs-Austin
– volume: 43
  start-page: 247
  issue: 4
  year: 2016
  end-page: 252
  article-title: F-18-nanobody for PET imaging of HER2 overexpressing tumors
  publication-title: Nucl Med Biol
– volume: 28
  start-page: 351
  issue: 10
  year: 2015
  end-page: 363
  article-title: An efficient protocol towards site-specifically clickable nanobodies in high yield: cytoplasmic expression in escherichia coli combined with intein-mediated protein ligation
  publication-title: Protein Eng Des Sel
– volume: 87
  start-page: 586
  issue: 5
  year: 2010
  end-page: 592
  article-title: Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer
  publication-title: Clin Pharmacol Ther
– volume: 6
  start-page: 355
  issue: 3
  year: 2013
  end-page: 363
  article-title: Novel antiplatelet agents: ALX-0081, a nanobody directed towards von willebrand factor
  publication-title: J Cardiovasc Transl
– volume: 18
  start-page: 193
  issue: 4
  year: 2012
  end-page: 200
  article-title: A dual role for genetically modified lymphocytes in cancer immunotherapy
  publication-title: Trends Mol Med
– volume: 7
  start-page: 303ra139
  issue: 303
  year: 2015
  article-title: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
  publication-title: Sci Transl Med
– volume: 19
  start-page: 403
  issue: 2
  year: 2018
  article-title: Nanobody based dual specific CARs
  publication-title: Int J Mol Sci
– volume: 10
  start-page: 167
  issue: 3
  year: 2008
  end-page: 175
  article-title: SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression
  publication-title: Mol Imaging Biol
– volume: 430
  start-page: 4369
  issue: 21
  year: 2018
  end-page: 4386
  article-title: Structural basis of epitope recognition by heavy-chain camelid antibodies
  publication-title: J Mol Biol
– volume: 374
  start-page: 168
  issue: 6518
  year: 1995
  end-page: 173
  article-title: A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks
  publication-title: Nature
– volume: 4
  start-page: 708
  issue: 7
  year: 2014
  end-page: 720
  article-title: Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody
  publication-title: Theranostics
– volume: 24
  start-page: 109
  issue: 2
  year: 2018
  end-page: 112
  article-title: Pricing of monoclonal antibody therapies: higher if used for cancer?
  publication-title: Am J Manag Care
– year: 2020
  article-title: Phase I trial of (131)I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
  publication-title: J Nucl Med
– volume: 20
  start-page: 1349
  issue: 12
  year: 2018
  end-page: 1360
  article-title: Tumour heterogeneity and metastasis at single-cell resolution
  publication-title: Nat Cell Biol
– volume: 7
  start-page: 876
  issue: 12
  year: 2011
  end-page: 884
  article-title: Choosing an effective protein bioconjugation strategy
  publication-title: Nat Chem Biol
– volume: 57
  start-page: 27
  issue: 1
  year: 2016
  end-page: 33
  article-title: Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma
  publication-title: J Nucl Med
– volume: 50
  start-page: 974
  issue: 6
  year: 2009
  end-page: 981
  article-title: Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging
  publication-title: J Nucl Med
– volume: 8
  start-page: 55
  issue: 4
  year: 2019
  article-title: Antibody structure and function: the basis for engineering therapeutics
  publication-title: Antibodies
– volume: 71
  start-page: 442
  issue: 1
  year: 2005
  end-page: 450
  article-title: Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo
  publication-title: Appl Environ Microbiol
– volume: 7
  start-page: e1002072
  issue: 6
  year: 2011
  article-title: High affinity nanobodies against the trypanosome brucei VSG are potent trypanolytic agents that block endocytosis
  publication-title: Plos Pathog
– volume: 129
  start-page: 2013
  issue: 8
  year: 2011
  end-page: 2024
  article-title: A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
  publication-title: Int J Cancer
– volume: 11
  start-page: 872
  issue: 6
  year: 2019
  article-title: Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent
  publication-title: Cancers (Basel)
– volume: 21
  start-page: 1076
  issue: 7
  year: 2016
  end-page: 1113
  article-title: Nanobodies as therapeutics: big opportunities for small antibodies
  publication-title: Drug Discov Today
– volume: 109
  start-page: 16642
  issue: 41
  year: 2012
  end-page: 16647
  article-title: Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
  publication-title: P Natl Acad Sci USA
– volume: 292
  start-page: 498
  issue: 5516
  year: 2001
  end-page: 500
  article-title: Expanding the genetic code of escherichia coli
  publication-title: Science
– volume: 323
  start-page: 269
  year: 2020
  end-page: 281
  article-title: Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session
  publication-title: J Control Release
– volume: 9
  start-page: 4664
  issue: 1
  year: 2018
  article-title: Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
  publication-title: Nat Commun
– volume: 72
  start-page: 544
  issue: 3
  year: 2006
  end-page: 551
  article-title: Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy
  publication-title: Appl Microbiol Biot
– volume: 6
  start-page: 14
  issue: 1
  year: 2016
  article-title: Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization
  publication-title: Ejnmmi Res
– volume: 2
  start-page: 77
  issue: 1
  year: 2010
  end-page: 83
  article-title: Antibody fragments hope and hype
  publication-title: Mabs-Austin
– volume: 4
  start-page: e11349
  year: 2015
  article-title: Nanobodies: site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation
  publication-title: Elife
– volume: 19
  start-page: 1645
  issue: 10
  year: 2002
  end-page: 1655
  article-title: Evolution of amino acid frequencies in proteins over deep time: Inferred order of introduction of amino acids into the genetic code
  publication-title: Mol Biol Evol
– volume: 3
  start-page: 887
  issue: 11
  year: 2006
  end-page: 889
  article-title: Targeting and tracing antigens in live cells with fluorescent nanobodies
  publication-title: Nat Methods
– volume: 3
  start-page: 544
  issue: 5
  year: 2003
  end-page: 550
  article-title: New technologies in therapeutic antibody development
  publication-title: Curr Opin Pharmacol
– volume: 16
  start-page: 3145
  issue: 7
  year: 2019
  end-page: 3156
  article-title: Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells
  publication-title: Mol Pharmaceut
– volume: 8
  start-page: 3471
  issue: 5
  year: 2017
  end-page: 3478
  article-title: Broad substrate tolerance of tubulin tyrosine ligase enables one-step site-specific enzymatic protein labeling
  publication-title: Chem Sci
– volume: 98
  start-page: 456
  issue: 3
  year: 2002
  end-page: 462
  article-title: Efficient tumor targeting by single-domain antibody fragments of camels
  publication-title: Int J Cancer
– volume: 13
  start-page: 399
  issue: 4
  year: 2013
  end-page: 406
  article-title: The first antibody therapy for cancer: a personal experience
  publication-title: Expert Rev Anticancer Ther
– volume: 7
  start-page: 1129
  issue: 9
  year: 1994
  end-page: 1135
  article-title: Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains
  publication-title: Protein Eng
– volume: 21
  start-page: 341
  issue: 3
  year: 2012
  end-page: 353
  article-title: Development of novel CXCR4-based therapeutics
  publication-title: Expert Opin Investig Drugs
– volume: 4
  start-page: 498
  issue: 6
  year: 2016
  end-page: 508
  article-title: T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B Cells
  publication-title: Cancer Immunol Res
– volume: 13
  start-page: 33
  year: 2015
  article-title: Characterization and applications of nanobodies against human procalcitonin selected from a novel naive nanobody phage display library
  publication-title: J Nanobiotechnol
– volume: 75
  start-page: 887
  issue: 5
  year: 2015
  end-page: 895
  article-title: Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic nanobody(R) targeting the DR5 receptor
  publication-title: Cancer Chemother Pharmacol
– volume: 380
  start-page: 1726
  issue: 18
  year: 2019
  end-page: 1737
  article-title: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
  publication-title: N Engl J Med
– volume: 209
  start-page: 633
  issue: 5
  year: 2015
  end-page: 644
  article-title: Nanobodies and recombinant binders in cell biology
  publication-title: J Cell Biol
– volume: 64
  start-page: 2853
  issue: 8
  year: 2004
  end-page: 2857
  article-title: Efficient cancer therapy with a nanobody-based conjugate
  publication-title: Cancer Res
– volume: 13
  start-page: 1149
  issue: 8
  year: 2016
  end-page: 1163
  article-title: Emerging site-specific bioconjugation strategies for radioimmunotracer development
  publication-title: Expert Opin Drug Deliv
– volume: 11
  start-page: 33
  issue: 1
  year: 2012
  end-page: 46
  article-title: Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody
  publication-title: Mol Imaging
– volume: 36
  start-page: 109
  issue: 2
  year: 2020
  end-page: 122
  article-title: Nanobodies: the future of antibody-based immune therapeutics
  publication-title: Cancer Biother Radiopharm
– volume: 3
  start-page: 17004
  year: 2017
  article-title: Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
  publication-title: Cell Discov
– volume: 40
  start-page: 3147
  issue: 9
  year: 1980
  end-page: 3154
  article-title: Serotherapy of a patient with a monoclonal-antibody directed against a human lymphoma-associated antigen
  publication-title: Cancer Res
– volume: 1830
  start-page: 5526
  issue: 12
  year: 2013
  end-page: 5534
  article-title: Albumin as a versatile platform for drug half-life extension
  publication-title: Biochim Biophys Acta
– volume: 17
  start-page: 141
  issue: 3
  year: 2017
  end-page: 141
  article-title: Epigenetic and genetic heterogeneity in metastasis
  publication-title: Nat Rev Cancer
– volume: 17
  start-page: 155
  issue: 2
  year: 2016
  end-page: 158
  article-title: A Nanobody activation immunotherapeutic that selectively destroys HER2-positive breast cancer cells
  publication-title: Chembiochem
– volume: 49
  start-page: 788
  issue: 5
  year: 2008
  end-page: 795
  article-title: Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
  publication-title: J Nucl Med
– volume: 373
  start-page: 941
  issue: 4
  year: 2007
  end-page: 953
  article-title: Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope
  publication-title: J Mol Biol
– volume: 60
  start-page: 1213
  issue: 9
  year: 2019
  end-page: 1220
  article-title: Early phase I study of a (99 m)Tc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer
  publication-title: J Nucl Med
– volume: 3
  start-page: 429
  issue: 6
  year: 2006
  end-page: 438
  article-title: Protein ligation: an enabling technology for the biophysical analysis of proteins
  publication-title: Nat Methods
– volume: 172
  start-page: 607
  issue: 3
  year: 2013
  end-page: 617
  article-title: Targeting tumors with nanobodies for cancer imaging and therapy
  publication-title: J Control Release
– volume: 7
  start-page: 254
  issue: 2
  year: 2012
  end-page: 264
  article-title: Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators
  publication-title: Contrast Media Mol Imaging
– volume: 3
  start-page: 803
  issue: 9
  year: 1996
  end-page: 811
  article-title: Crystal structure of a camel single-domain V-H antibody fragment in complex with lysozyme
  publication-title: Nat Struct Biol
– volume: 16
  start-page: 861
  issue: 5
  year: 2015
  end-page: 867
  article-title: Microbial transglutaminase and c-myc-tag: a strong couple for the functionalization of antibody-like protein scaffolds from discovery platforms
  publication-title: Chembiochem
– volume: 27
  start-page: 198
  issue: 1
  year: 2016
  end-page: 206
  article-title: Incorporation of a doubly functionalized synthetic amino acid into proteins for creating chemical and light-induced conjugates
  publication-title: Bioconjug Chem
– volume: 103
  start-page: 4586
  issue: 12
  year: 2006
  end-page: 4591
  article-title: Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
  publication-title: P Natl Acad Sci USA
– volume: 10
  start-page: 1441
  issue: 7
  year: 2014
  end-page: 1451
  article-title: Nanobody-photosensitizer conjugates for targeted photodynamic therapy
  publication-title: Nanomed-Nanotechnol
– volume: 23
  start-page: 624
  issue: 7-8
  year: 2017
  end-page: 630
  article-title: N-terminal chemical protein labeling using the naturally split GOS-TerL intein
  publication-title: J Pept Sci
– volume: 98
  start-page: 777
  issue: 2
  year: 2001
  end-page: 777
  article-title: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas (vol 97, pg 12846, 2000)
  publication-title: P Natl Acad Sci USA
– volume: 175
  start-page: 3769
  issue: 6
  year: 2005
  end-page: 3779
  article-title: Expression of a dromedary heavy chain-only antibody and B cell development in the mouse
  publication-title: J Immunol
– volume: 18
  start-page: 823
  issue: 4
  year: 2019
  end-page: 833
  article-title: Nanobody targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies
  publication-title: Mol Cancer Ther
– volume: 363
  start-page: 446
  issue: 6428
  year: 1993
  end-page: 448
  article-title: Naturally-occurring antibodies devoid of light-chains
  publication-title: Nature
– volume: 14
  start-page: 405
  issue: 6
  year: 2012
  end-page: 415
  article-title: Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
  publication-title: J Gene Med
– volume: 54
  start-page: 776
  issue: 5
  year: 2013
  end-page: 784
  article-title: Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer
  publication-title: J Nucl Med
– volume: 18
  start-page: 5
  issue: 1
  year: 2019
  article-title: Evaluation of scFv protein recovery from E-coli by in vitro refolding and mild solubilization process
  publication-title: Microb Cell Fact
– volume: 27
  start-page: 1
  issue: 1
  year: 2020
  article-title: Development of therapeutic antibodies for the treatment of diseases
  publication-title: J Biomed Sci
– volume: 128
  start-page: 178
  issue: 1-3
  year: 2009
  end-page: 183
  article-title: Camelid immunoglobulins and nanobody technology
  publication-title: Vet Immunol Immunop
– volume: 47
  start-page: 2107
  issue: 6
  year: 2015
  end-page: 2114
  article-title: Feasibility study of the fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool
  publication-title: Int J Oncol
– volume: 40
  start-page: 1718
  issue: 11
  year: 2013
  end-page: 1729
  article-title: Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 66
  start-page: 24
  issue: 1
  year: 2006
  end-page: 28
  article-title: Rhabdomyosarcoma lysis by T cells expressing a human autoantibody- based chimeric receptor targeting the fetal acetylcholine receptor
  publication-title: Cancer Res
– volume: 116
  start-page: 16656
  issue: 33
  year: 2019
  end-page: 16656
  article-title: Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice (vol 116, pg 7624, 2019)
  publication-title: P Natl Acad Sci USA
– volume: 34
  start-page: 11
  issue: 1
  year: 2020
  end-page: 26
  article-title: The therapeutic potential of nanobodies
  publication-title: Biodrugs
– volume: 35
  year: 2008
  article-title: SPECT/CT imaging with 99mTc-depreotide in lymphoma. comparison to Ga-67 scintigraphy
  publication-title: Eur J Nucl Med Mol I
– volume: 82
  start-page: 775
  year: 2013
  end-page: 797
  article-title: Nanobodies: natural single-domain antibodies
  publication-title: Annu Rev Biochem
– volume: 23
  start-page: 411
  issue: 4
  year: 2008
  end-page: 423
  article-title: Tumor targeting by a multivalent single-chain Fv (scFv) anti-lewis Y antibody construct
  publication-title: Cancer Biother Radio
– volume: 12
  start-page: 352
  year: 2014
  article-title: Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1
  publication-title: J Transl Med
– volume: 30
  start-page: 205
  issue: 2
  year: 2013
  end-page: 209
  article-title: Development of VEGFR2-specific nanobody pseudomonas exotoxin a conjugated to provide efficient inhibition of tumor cell growth
  publication-title: N Biotechnol
– volume: 25
  start-page: 979
  issue: 5
  year: 2014
  end-page: 988
  article-title: Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging
  publication-title: Bioconjugate Chem
– volume: 14
  start-page: 1247
  issue: 13
  year: 2003
  end-page: 1254
  article-title: In vivo tracking of neural progenitor cell migration to glioblastomas
  publication-title: Hum Gene Ther
– volume: 8
  start-page: 1442
  year: 2017
  article-title: Nanobody-based delivery systems for diagnosis and targeted tumor therapy
  publication-title: Front Immunol
– volume: 6
  start-page: 583
  issue: 8
  year: 2006
  end-page: 592
  article-title: Drug penetration in solid tumours
  publication-title: Nat Rev Cancer
– volume: 12
  start-page: 738
  issue: 3
  year: 2020
  article-title: Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence
  publication-title: Cancers
– volume: 23
  start-page: 4926
  issue: 41
  year: 2005
  end-page: 4934
  article-title: Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins
  publication-title: Vaccine
– volume: 55
  start-page: 528
  issue: 2
  year: 2016
  end-page: 533
  article-title: Enzyme-mediated modification of single-domain antibodies for imaging modalities with different characteristics
  publication-title: Angew Chem Int Edit
– volume: 24
  start-page: 1852
  issue: 12
  year: 2018
  end-page: 1858
  article-title: (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
  publication-title: Nat Med
– ident: bibr63-15330338211010117
  doi: 10.1016/j.nano.2013.12.007
– ident: bibr38-15330338211010117
  doi: 10.1093/oxfordjournals.molbev.a003988
– ident: bibr49-15330338211010117
  doi: 10.1093/protein/gzv032
– ident: bibr69-15330338211010117
  doi: 10.1158/0008-5472.CAN-05-0542
– ident: bibr65-15330338211010117
  doi: 10.1021/acs.molpharmaceut.9b00360
– ident: bibr85-15330338211010117
  doi: 10.1038/s41467-018-07131-y
– ident: bibr24-15330338211010117
  doi: 10.1016/j.bbagen.2013.04.023
– ident: bibr82-15330338211010117
  doi: 10.1038/nrc.2017.11
– ident: bibr8-15330338211010117
  doi: 10.1016/j.jconrel.2013.08.298
– ident: bibr81-15330338211010117
  doi: 10.3390/cancers12030738
– ident: bibr55-15330338211010117
  doi: 10.1007/s00280-015-2712-0
– ident: bibr35-15330338211010117
  doi: 10.1158/0008-5472.CAN-03-3935
– ident: bibr21-15330338211010117
  doi: 10.1016/j.vetimm.2008.10.299
– ident: bibr44-15330338211010117
  doi: 10.1002/anie.201507596
– ident: bibr90-15330338211010117
  doi: 10.1186/s13550-016-0166-y
– ident: bibr20-15330338211010117
  doi: 10.1073/pnas.0505379103
– ident: bibr46-15330338211010117
  doi: 10.1002/cbic.201500009
– ident: bibr91-15330338211010117
  doi: 10.1586/era.13.16
– ident: bibr53-15330338211010117
  doi: 10.1517/13543784.2012.656197
– ident: bibr89-15330338211010117
  doi: 10.1007/s00259-013-2471-2
– ident: bibr18-15330338211010117
  doi: 10.1126/science.aaa5026
– ident: bibr28-15330338211010117
  doi: 10.1093/protein/7.9.1129
– ident: bibr95-15330338211010117
  doi: 10.1016/j.jmb.2007.08.027
– ident: bibr77-15330338211010117
  doi: 10.2967/jnumed.108.060392
– ident: bibr88-15330338211010117
  doi: 10.2310/7290.2011.00025
– ident: bibr52-15330338211010117
  doi: 10.1158/1535-7163.MCT-18-0849
– ident: bibr62-15330338211010117
  doi: 10.1089/104303403767740786
– ident: bibr57-15330338211010117
  doi: 10.1038/celldisc.2017.4
– ident: bibr87-15330338211010117
  doi: 10.2967/jnumed.118.224170
– ident: bibr11-15330338211010117
  doi: 10.1083/jcb.201409074
– ident: bibr73-15330338211010117
  doi: 10.1007/s11307-008-0133-8
– ident: bibr70-15330338211010117
  doi: 10.1126/scitranslmed.aac5415
– ident: bibr86-15330338211010117
  doi: 10.3390/cancers11060872
– ident: bibr64-15330338211010117
  doi: 10.1016/j.jconrel.2016.03.014
– ident: bibr17-15330338211010117
  doi: 10.1186/s12951-018-0392-8
– volume: 35
  year: 2008
  ident: bibr23-15330338211010117
  publication-title: Eur J Nucl Med Mol I
– ident: bibr3-15330338211010117
  doi: 10.3390/antib8040055
– ident: bibr75-15330338211010117
  doi: 10.2967/jnumed.112.111021
– ident: bibr76-15330338211010117
  doi: 10.1038/clpt.2010.12
– ident: bibr80-15330338211010117
  doi: 10.7150/thno.8156
– ident: bibr13-15330338211010117
  doi: 10.1038/363446a0
– ident: bibr16-15330338211010117
  doi: 10.1146/annurev-biochem-063011-092449
– ident: bibr59-15330338211010117
  doi: 10.1056/NEJMoa1817226
– ident: bibr83-15330338211010117
  doi: 10.1038/s41556-018-0236-7
– ident: bibr37-15330338211010117
  doi: 10.7554/eLife.11349
– ident: bibr92-15330338211010117
  doi: 10.1007/s00253-005-0300-7
– ident: bibr22-15330338211010117
  doi: 10.1038/nsb0996-803
– ident: bibr36-15330338211010117
  doi: 10.1073/pnas.1202832109
– ident: bibr54-15330338211010117
  doi: 10.2967/jnumed.120.255679
– ident: bibr6-15330338211010117
  doi: 10.1038/nrc1893
– ident: bibr42-15330338211010117
  doi: 10.1021/acs.bioconjchem.5b00602
– ident: bibr67-15330338211010117
  doi: 10.1002/jgm.2604
– ident: bibr84-15330338211010117
  doi: 10.1038/s41591-018-0255-8
– ident: bibr41-15330338211010117
  doi: 10.1126/science.1060077
– ident: bibr39-15330338211010117
  doi: 10.1021/bc500111t
– ident: bibr97-15330338211010117
  doi: 10.1128/AEM.71.1.442-450.2005
– ident: bibr12-15330338211010117
  doi: 10.4161/mabs.2.1.10786
– ident: bibr33-15330338211010117
  doi: 10.1038/nmeth953
– ident: bibr78-15330338211010117
  doi: 10.1016/j.nucmedbio.2016.01.002
– ident: bibr50-15330338211010117
  doi: 10.1002/psc.2996
– ident: bibr96-15330338211010117
  doi: 10.4049/jimmunol.175.6.3769
– ident: bibr43-15330338211010117
  doi: 10.1038/nchembio.720
– ident: bibr72-15330338211010117
  doi: 10.3390/ijms19020403
– ident: bibr25-15330338211010117
  doi: 10.1002/ijc.26145
– ident: bibr51-15330338211010117
  doi: 10.1038/nmeth886
– ident: bibr66-15330338211010117
  doi: 10.1016/j.jconrel.2020.04.030
– volume: 23
  start-page: 411
  issue: 4
  year: 2008
  ident: bibr10-15330338211010117
  publication-title: Cancer Biother Radio
– volume: 116
  start-page: 16656
  issue: 33
  year: 2019
  ident: bibr71-15330338211010117
  publication-title: P Natl Acad Sci USA
  doi: 10.1073/pnas.1912487116
– ident: bibr4-15330338211010117
  doi: 10.3389/fimmu.2017.01442
– ident: bibr26-15330338211010117
  doi: 10.1016/j.vaccine.2005.05.017
– ident: bibr79-15330338211010117
  doi: 10.1002/cmmi.491
– ident: bibr27-15330338211010117
  doi: 10.1186/s12934-019-1053-9
– ident: bibr58-15330338211010117
  doi: 10.1158/2326-6066.CIR-15-0231
– ident: bibr74-15330338211010117
  doi: 10.2967/jnumed.107.048538
– ident: bibr30-15330338211010117
  doi: 10.1007/s12265-012-9435-y
– ident: bibr31-15330338211010117
  doi: 10.1016/j.drudis.2016.04.003
– ident: bibr32-15330338211010117
  doi: 10.4161/19420862.2014.975099
– ident: bibr60-15330338211010117
  doi: 10.1089/cbr.2020.3941
– ident: bibr2-15330338211010117
  doi: 10.1016/j.coph.2003.05.002
– ident: bibr93-15330338211010117
  doi: 10.1371/journal.ppat.1002072
– volume: 24
  start-page: 109
  issue: 2
  year: 2018
  ident: bibr7-15330338211010117
  publication-title: Am J Manag Care
– ident: bibr48-15330338211010117
  doi: 10.1039/C7SC00574A
– volume: 98
  start-page: 777
  issue: 2
  year: 2001
  ident: bibr61-15330338211010117
  publication-title: P Natl Acad Sci USA
  doi: 10.1073/pnas.98.2.777-e
– ident: bibr9-15330338211010117
  doi: 10.3892/ijo.2015.3210
– ident: bibr19-15330338211010117
  doi: 10.1016/j.jmb.2018.09.002
– ident: bibr34-15330338211010117
  doi: 10.1016/j.nbt.2012.09.002
– ident: bibr94-15330338211010117
  doi: 10.1186/s12951-015-0091-7
– ident: bibr5-15330338211010117
  doi: 10.1186/s12929-019-0592-z
– ident: bibr45-15330338211010117
  doi: 10.1002/cbic.201500591
– ident: bibr15-15330338211010117
  doi: 10.1007/s40259-019-00392-z
– ident: bibr40-15330338211010117
  doi: 10.1080/17425247.2016.1178235
– ident: bibr14-15330338211010117
  doi: 10.1038/374168a0
– ident: bibr56-15330338211010117
  doi: 10.2967/jnumed.115.162024
– ident: bibr68-15330338211010117
  doi: 10.1016/j.molmed.2011.12.003
– ident: bibr29-15330338211010117
  doi: 10.1002/ijc.10212
– volume: 40
  start-page: 3147
  issue: 9
  year: 1980
  ident: bibr1-15330338211010117
  publication-title: Cancer Res
– ident: bibr47-15330338211010117
  doi: 10.1186/s12967-014-0352-5
SSID ssj0026631
Score 2.3771458
SecondaryResourceType review_article
Snippet Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 15330338211010117
SubjectTerms Amino acids
Antibodies
Antigens
Binding sites
Bioengineering
Cancer
Cancer research
Cancer therapies
Chemical bonds
Crystal structure
Cytotoxicity
Epidermal growth factor
Fluorophores
Immunogenicity
Medical research
Nanobodies
Pharmacokinetics
Proteins
Review
Side effects
Targeted cancer therapy
Tomography
Toxins
Tumor cells
SummonAdditionalLinks – databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aQXwprZ_bD1lBEITFfO0miw-ih6UK9amFe1uSTNYPdLf27h78753J5e48Wvu4ye6STCaT30yG3zD20nGNPeAqiOArHWRbWWlkBd5Ag_4EQm4K6J99aU4v9OdpPc0Bt1lOq1zZxGSoYQwUI3-DSF_J1mrF313-rqhqFN2u5hIad9k9oi4jrTbTjcOFp2nmS1UVV7rJt5pEuERtHN0z8n8E8aJtnUuJvv8mzHk9dfKf_K90JJ3ssd2MJcv3y8XfZ3fi8JDdP8u35Y_YWzSdox_hTzkZhx8LCpjNSgSp5XlK_45QTmjN8XlJLVC6AcpPv1Ldosfs4uTj-eS0ysUSqoCgZU5WDVzwFsUde66ChAAtEc4Fq3xthXPCQBQueq4897F2DlpsDi3UGn0w9YTtDOMQn7FS-z4qo3oAa7XwBtezRZQlI48W8Z8vGF-JqguZSZwKWvzsRCYPvybdgr1ef3K5pNG47eUPJP_1i8SAnRrGq69d3lAdIilniNNU2Ea3fXBoiITxdZA9QtAeB3m0Wr0ub8tZt1GiG7sVwUvdWKkK9mLdjfuNLlHcEMcF_qKWKFT045qCPV3qwnqgisAmnh4FM1tasjWT7Z7h-7fE6W0F8SLhP1-RPm2G9F8hHdw-v0P2QFL2TQoWHbGd-dUiHiN8mvvnaY_8BVjQEEs
  priority: 102
  providerName: ProQuest
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9RAFD7ULYgvUq-NrRJBEITYzCXJBB-kLi5VqA-yxb6FuUUrbiLt5qH_3nOSSXTpKj5mZpJMTs7MfOcy3wC80KnEGqcT551JpOVlonjBE2cKl6M9gZCbHPqnn_KTM_nxPDvfgXbcCxMkePWa0qqwR_1kTaObvNFHIch4RCAlReOKrBdGrGZvu_WqGtzd46kaVELx6W5FoW1LCZHXybi97Rbs8iLP-Ax2jxefvywnGw0X4ECxKpJUyDwEQre-dGMp6xn_t8HUm9mWf6SM9avYYg_uBvgZHw_6cg92fHMfbp-GAPsDeIOzbWtadx3P2-Z7Rz62qxhxbbzsM8a9i-ekJng9sBHEunHxh1V_1NFDOFu8X85PknC-QmIR56xpInTaGoV_yNepsNxZVxJHnVXCZIppzQrnmfYmFSY1PtPalVhsS5dJNNvEI5g1beP3IZam9qIQtXNKSWYKVIESgRn3qVcIGU0E6SiqygbycToD40fFAt_4DelG8Gq65efAvPGvxu9I_lNDIs3uC9rLr1UYgxWCL10QDSpTuSxrq3HuYoXJLK8RtdbYycPx71WjHlZoYQpeKinSrdWCEKnMFRcRPJ-qcYhS3EU3vu3wERlHoaLpl0fweNCFqaOC8CkuOBEUG1qy8SWbNc3Ft54GXDGiUsJnviR9-t2lvwrpyX-3PIA7nHJ3elfTIczWl51_iuBrbZ6FAfMLgaIjtw
  priority: 102
  providerName: SAGE Publications
Title Nanobody Conjugates for Targeted Cancer Therapy and Imaging
URI https://journals.sagepub.com/doi/full/10.1177/15330338211010117
https://www.ncbi.nlm.nih.gov/pubmed/33929911
https://www.proquest.com/docview/2613298430
https://www.proquest.com/docview/3232446823
https://www.proquest.com/docview/2520871746
https://pubmed.ncbi.nlm.nih.gov/PMC8111546
https://doaj.org/article/643a7913918649fca88017b5c2f057fb
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7SBEovpW36cJsuDhQCAVPrYUump2TJkgYSStiQvRm9TFoaOzS7h_77ztjabZak7aUnY0kW8mik-UYavgH4YHKJNd5kPnibScerTHPFM2-VL9GfQMhNB_qnZ-XxhTyZFbM7qb4oJmygBx4E9xEtplHEXcl0KavGGVQ4pmzheINQo7G0-6LNWzpT0dVCO8riHSbRKxGoydEZI2-HEQvamhXqyfofQpj3AyXvRHv1BmjyDJ5G5JgeDCN-DhuhfQGPT-Pd-DZ8wo2ys53_mY679tuCjsduU4Sk6bQP9g4-HdMM4_tAJJCa1qefr_ssRS_hYnI0HR9nMTVC5hCizGkP88ZZjcINTS4c985XRC_ntLCFZsYw5QMzwebC5jYUxvgKi13lC4kel3gFm23XhjeQStsEoUTjvdaSWYWzVyGm4iEPGtGeTSBfiqp2kTec0ld8r1mkCr8n3QT2V5_cDKQZf2t8SPJfNSS-674AtaCOWlD_SwsS2FnOXh0X4W2NzqHglZYif7BaEJiUpeYigd1VNa4uujIxbegW2EXBUajotZUJvB50YTVQQdASbUUCak1L1v5kvab9etUzeGtGLEjY5x7p0-8h_VFIb_-HkN7BE04ROf0B0g5szn8swnuEVHM7gkdqpkawdTA5v5zi8_Do7Mv5qF9TvwBJnxo0
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VIgEviJuUAkECISFFOLaTOEIIwUK1S7t92kr7FnyFQ5C03V1V_VP9jczk2GXV0rc-xk4sZzLHN7bzDcBLzST2OB0570wkLc8jxTMeOZO5FPMJhNy0oD_eT4cH8us0mW7AWf8vDB2r7H1i46hdbWmN_C0ifcFzJQX7cHgUUdUo2l3tS2i0arHrT08wZZu9H33G7_uK850vk8Ew6qoKRBaj-5zM32lrFM7Ll0xY7qzLiZnNKmESFWsdZ87H2hsmDDM-0drl2Gxzl0hMVgSOew2uY-BllOxl01WCh9G742cVERMy7XZRieCJ2himg5RvxcTDthYHm3IBF2Hc80c1_zlv1oTAnTtwu8Ou4cdW2e7Chq_uwY1xtzt_H96hq65N7U7DQV39WtAC3SxEUBxOmuPm3oUD0jG8bqkMQl25cPSnqZP0AA6uRIwPYbOqK_8YQmlKLzJROqeUjE2G-pMjquOeeYV40wTAelEVtmMupwIav4u4Iys_J90A3iwfOWxpOy67-RPJf3kjMW43DfXx96Iz4AKRm86IQzVWqcxLq9HxxZlJLC8R8pY4ye3-6xWdG5gVK6W9sFsQnJWp4iKAF8tutG_atNGVrxc4RMJRqJg3pgE8anVhOVFB4BajVQDZmpasvcl6T_XzR8MhrmLiYcIxX5M-rab0XyFtXf5-z-HmcDLeK_ZG-7tP4Bankz_NQtU2bM6PF_4pQre5edbYSwjfrtpA_wLWlk6i
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB7BVqq4oJZXQwsECQkJKdSvJI44tQurFmiF0Fb0FvkVHoKkancP_Htmst7AqgviGNuxnBnP-Bt78hngmWEKa7zJfPA2U05UmRalyLwtfYHxBEJu2tA_OS2OztTb8_w8brjRvzBRglcvKa0KR9Q7a7LuC9_sxzPGfcIoDGMrCl44kZrdhA2lMMgbwcbB5OOn6RBy4XoaGVNlxqQq4rnm2k5WVqaewH8d6ryePPlHBli_KE224HZEk-nBQv3bcCO0d2DzJJ6X34VX6Dw72_mf6bhrv81py-wqRZiaTvsE8ODTMWkdnxfkAqlpfXr8o7-56B6cTd5Mx0dZvC4hcwhbZuTXvHFWo8BDw6QT3vmKKOecljbX3Bhe-sBNsExaZkNujK-w2FU-VxiFyfswars27ECqbBNkKRvvtVbclqjRCnGWCCxoRIA2AbYUVe0ilzhdafG95pE-_Jp0E3gxvHKxINL4V-NDkv_QkDiw-4Lu8nMdTapGLGVKYjXlulBV4wy6Il7a3IkGQWiDg9xbaq9eTqsaA0YpKq0kW1stCWCqQguZwNOhGi2OjlFMG7o5dpELFCpGckUCDxZzYRioJLiJ60cC5cosWfmS1Zr265ee1VtzYkbCPp_TfPo9pL8K6eF_t3wCmx9eT-r3x6fvduGWoKycfhNpD0azy3l4hLBqZh9H2_kFyPsSMA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanobody+Conjugates+for+Targeted+Cancer+Therapy+and+Imaging&rft.jtitle=Technology+in+cancer+research+%26+treatment&rft.au=Kang%2C+Wei&rft.au=Ding+Chuanfeng&rft.au=Zheng+Danni&rft.au=Ma%2C+Xiao&rft.date=2021-01-01&rft.pub=Sage+Publications+Ltd&rft.issn=1533-0346&rft.eissn=1533-0338&rft.volume=20&rft_id=info:doi/10.1177%2F15330338211010117&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1533-0346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1533-0346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1533-0346&client=summon